All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
FDA places a clinical hold on allogeneic CAR T cell trials
On October 7, 2021, the U.S. Food and Drug Administration (FDA) placed a clinical hold on a series of trials investigating the use of allogeneic chimeric antigen receptor (allo-CAR) T-cell...
End of the LYRA study: DARA + VCd induction therapy followed by DARA maintenance
Daratumumab or DARA is a human IgG kappa monoclonal antibody and is approved as monotherapy or in combination with standard of care regimens to treat newly diagnosed...
"The MM Hub is the ideal platform for the latest news about myeloma. You will find information about the most recent data, and also personal experiences from experts managing myeloma patients in their clinical practice."
Your opinion matters